Paris-based Sanofi announced that its olipudase alfa had positive results in two different clinical trials for the treatment of acid sphingomyelinase deficiency (ASMD), also known as Nieman-Pick disease. Olipudase alfa is an investigational recombinant human acid sphingomyelinase.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,